MPL proto-oncogene, thrombopoietin receptor. Every medicine in our data that ChEMBL or the Guide to Pharmacology records as acting on this protein, with the source for each and its current clinical trials on this site.
| Medicine | How it acts | Source | Current trials here |
|---|---|---|---|
| Eltrombopag CHEMBL461101 |
Thrombopoietin receptor agonist Agonist Small molecule |
✓ Both | 13 |
| Romiplostim CHEMBL1201832 |
Thrombopoietin receptor agonist Agonist Protein |
✓ Both | 6 |
| Avatrombopag CHEMBL2103883 |
Thrombopoietin receptor agonist Agonist Small molecule |
✓ Both | 5 |
| Hetrombopag CHEMBL4297764 |
Thrombopoietin receptor agonist Agonist Unknown |
✓ Both | 4 |
| Lusutrombopag CHEMBL2107831 |
Thrombopoietin receptor agonist Agonist Small molecule |
✓ Both | 2 |
“Both” means ChEMBL and the Guide to Pharmacology each record this medicine acting on this protein; “only” means one source records it and the other does not (often because it lists fewer secondary targets). The Guide to Pharmacology adds a medicine here only when this protein is its primary target. Medicines without a link have no page on this site yet.
| Disease | Medicines tested | Furthest trial phase |
|---|---|---|
| Aplastic anemia | 3 | Phase 3 |
| Autoimmune thrombocytopenic purpura | 3 | Phase 3 |
| Hepatitis C virus infection | 3 | Phase 3 |
| Myelodysplastic syndrome | 2 | Phase 2/3 |
| Wiskott-Aldrich syndrome | 2 | Phase 2 |
| Acute myeloid leukemia | 2 | Phase 2 |
| Thrombocytopenia | 1 | Phase 3 |
| Chronic hepatitis C virus infection | 1 | Phase 3 |
| Severe aplastic anemia | 1 | Phase 3 |
| Paroxysmal nocturnal hemoglobinuria | 1 | Phase 2/3 |
| Abnormal bleeding | 1 | Phase 2 |
| B-cell chronic lymphocytic leukemia | 1 | Phase 2 |
| Bone marrow hypocellularity | 1 | Phase 2 |
| Fanconi anemia | 1 | Phase 2 |
| Acute graft vs. host disease | 1 | Phase 2 |
From ChEMBL's drug-disease records, which draw on trial registries. A trial phase is not an approval; approved uses are on each medicine's page from the regulators' own records.
Which medicines act on this protein comes from two independent, expert-curated sources: ChEMBL's mechanism-of-action records (via the Open Targets Platform) and the IUPHAR/BPS Guide to PHARMACOLOGY. Each row says which of them lists it. Data from them is shared here under their share-alike licences (CC BY-SA 3.0 and 4.0).
A job re-reads both sources every 30 days. Medicines are matched to our pages by exact name or a ChEMBL-curated synonym, and to the Guide to Pharmacology by ChEMBL ID or exact name, never by a close spelling. No AI drafting. See our methodology. The Open Targets data on this page was last retrieved on 30 Sep 2026. How every register is built: methodology · fixes we have made: corrections log.
